

press release

Embargoed to 16.00 BST 11 June 2026

Wegovy® ▼ pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK

Novo Nordisk's semaglutide tablets now approved by MHRA and will be available on private prescription within weeks to eligible adults living with obesity or overweight with a weight-related condition

- Approval is based on results from the OASIS 4 trial, which investigated semaglutide tablets 25mg in adults living with obesity and overweight versus placebo in addition to diet and exercise.¹
 - After 64 weeks, adults taking semaglutide tablets lost an average of ~17% (16.6%) body weight if they remained on treatment, compared with ~3% (2.7%) for placebo.¹
 - When all participants were included - regardless of if they remained on treatment - the average weight loss was ~14% (13.6%) versus ~2% (2.4%) with placebo.¹
- Semaglutide tablets will be available as a once-daily treatment, an alternative to weekly injections for adults living with obesity, or overweight with a weight-related condition, alongside diet and exercise.
- After this approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA), Novo Nordisk anticipates this medicine will be available via private prescription within weeks and is continuing to work with relevant organisations to expand access and support eligible patients on their weight management journey.

Gatwick, United Kingdom, 11 June 2026 – A new daily weight management pill has been approved in the UK, as an adjunct to a reduced calorie diet and increased physical activity, offering a first-of-its-kind alternative to injectable treatments, for adults.

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Wegovy®▼ pill (semaglutide tablets), an oral glucagon-like peptide-1 (GLP-1) receptor agonist licensed for weight management in adults living with obesity (initial Body Mass Index (BMI) ≥ 30 kg/m²), or overweight (BMI ≥ 27 kg/m² to < 30 kg/m²), with at least one weight-related condition.

The MHRA approval is based on data from the OASIS 4 phase 3 clinical trial. When evaluating the effect of treatment regardless of adherence, adults with obesity receiving semaglutide tablets 25mg achieved ~14% (13.6%) weight loss vs ~2% (2.4%) with placebo after 64 weeks, in addition to lifestyle modifications. Results showed that if all participants adhered to treatment, semaglutide 25 mg achieved weight loss of ~17% (16.6%) vs ~3% (2.7%) placebo after 64 weeks.¹

The study evaluated semaglutide tablets 25mg in 307 adults with obesity, or overweight with at least one weight-related condition, without diabetes.¹ In the study, the most commonly reported side effects were gastrointestinal, including nausea, vomiting and diarrhoea, reported by 74.0% participants in the oral semaglutide group and by 42.2% in the placebo group respectively.¹ These side effects were generally mild-to-moderate and transient. In OASIS 4, adverse events leading to treatment discontinuation occurred in ~7% (6.9%) of participants receiving oral semaglutide, which is consistent with rates observed in trials of injectable semaglutide.¹

"This marks an important milestone for obesity care in the UK," said Sebnem Avsar Tuna, General Manager at Novo Nordisk UK. "For the first time, people living with obesity have access to a GLP-1 treatment in a daily pill, allowing them the choice and flexibility of oral treatment to support their long-term weight management."

Professor Naveed Sattar, Professor of Cardiometabolic Medicine at the School of Cardiovascular & Metabolic Health at the University of Glasgow, said: "The approval of the once-daily oral form of Wegovy (semaglutide) is welcome news for people living with obesity, particularly those who would prefer not to use injections. Expanding the range of effective treatments is important in helping people sustainably reduce caloric intakes within an increasingly obesogenic environment. With obesity rates in the UK now at very high levels, and associated with substantial multimorbidity, additional treatment options for sustained weight loss are greatly needed."

"This is a landmark approval, making the UK the first country in Europe to approve Wegovy® pill," said Emil Kongshøj Larsen, Executive Vice President, International Operations, Novo Nordisk. "Today, around 15 million people in the UK are living with obesity, yet only a small proportion of them have access to treatment and we hope this approval supports increasing access to obesity care in the UK. With the introduction of this option for weight management,

we have an opportunity to support many more eligible patients. Most importantly, this gives patients another option — one that may fit their lives and help them reach their health goals.”

Novo Nordisk has previously announced plans to launch this medicine in select markets in the second half of 2026. The MHRA is the third regulatory authority to license the medicine, after the United States, Food and Drug Administration (FDA) and United Arab Emirates, Emirates Drug Establishment (EDE).

OASIS 4 results¹

The OASIS 4 trial included two pre-specified analyses: an on-treatment analysis assessing outcomes if all participants remained on treatment, and a treatment policy analysis reflecting outcomes regardless of treatment discontinuation.

About obesity

Obesity is a complex, chronic disease² affecting around 15 million people in the UK³ with 71% of adults in the UK projected to be living with obesity or overweight by 2040⁴. The condition requires long-term management. Treatment options should be individualised, with decisions about pharmacotherapy made jointly by healthcare professionals and patients^{2,5}.

About the OASIS 4 trial^{1,6}

OASIS 4 was a randomised, double-blind, placebo-controlled phase 3 clinical trial evaluating the efficacy and safety of semaglutide 25mg tablets in adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with at least one weight-related comorbidity, without type 2 diabetes. The trial had two co-primary endpoints: change in body weight (%) and the proportion achieving $\geq 5\%$ weight loss at week 64.^{1,6} 307 participants were randomised 2:1 to receive semaglutide 25mg tablets or placebo once daily for 64 weeks in addition to lifestyle interventions.^{1,6} All participants received advice on diet and physical activity, including a daily 500 kcal calorie deficit and a structured exercise regimen.^{1,6}

About Novo Nordisk

Novo Nordisk is a leading global healthcare company with a heritage of more than 100 years in diabetes care. Building on this foundation, our purpose is to drive change to defeat serious chronic diseases — from diabetes and obesity to rare blood and endocrine disorders — by pioneering scientific breakthroughs, expanding access to medicines, and working to prevent and ultimately cure disease. We are committed to long-term, responsible business practices that deliver financial, social and environmental value. Headquartered in Denmark and operating in around 80 countries, Novo Nordisk employs approximately 67,900 people and markets products in roughly 170 countries. For more information, visit www.novonordisk.co.uk.

Contacts for further information

Media:

Becky Hess

+44 7825 208077

rcme@novonordisk.com

Callum Haire

+44 7867 42963

lcmh@novonordisk.com

References

- ¹ Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. *N Engl J Med*. 2025;393:1077-87. Available from: https://www.nejm.org/doi/10.1056/NEJMoa2500969?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed. Accessed June 2026.
- ² World Health Organisation. Obesity and overweight; 7 May 2025. Available from: <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>. Last accessed June 2026.
- ³ A Novo Nordisk commissioned report. Frontier Economics. Estimating the full costs of obesity; 26 January 2022. Available from: <https://www.frontier-economics.com/media/hgwd4e4a/the-full-cost-of-obesity-in-the-uk.pdf>. Last accessed June 2026
- ⁴ Cancer Research UK. New analysis estimates over 21 million UK adults will be obese by 2040; 19 May 2022. Available from: <https://news.cancerresearchuk.org/2022/05/19/new-analysis-estimates-over-21-million-uk-adults-will-be-obese-by-2040/> Last accessed: June 2026
- ⁵ National Institute for Health and Care Excellence (NICE). *Overweight and obesity management (NG246)*. 2023. Available from: <https://www.nice.org.uk/guidance/ng246>
- ⁶ ClinicalTrials.gov. Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range (OASIS 4). Available from: <https://classic.clinicaltrials.gov/ct2/show/NCT05564117> Last accessed: June 2026.